New FedEx Life Sciences Unit Integrates Healthcare Logistics Capabilities
- Jul 20
- 2 min read
FedEx has launched FedEx Life Sciences, a new division offering specialized logistics for pharmaceuticals, medical devices, biologics, clinical trial drugs, and other critical healthcare shipments. It's part of a broader industry shift — also seen at UPS and DHL — away from legacy parcel delivery toward higher-margin, premium segments like healthcare, a market FedEx estimates at $80 billion.
The new unit consolidates capabilities across FedEx's parcel and supply chain organizations under one team with dedicated, advanced monitoring. FedEx generated about $10 billion in healthcare revenue over the past 12 months (up from $9 billion the prior fiscal year); UPS reports similar healthcare revenue, and DHL is targeting more than $10 billion by 2030.
Life sciences shipments (vaccines, tissue and blood samples, gene/protein therapies) are highly regulated and sensitive to temperature and environmental conditions, making speed, precision, visibility, and reliability more important than price. FedEx already operates six global life sciences centers and temperature-controlled corridors between key markets, including direct Dublin-Indianapolis flights launched last year connecting two major biopharma hubs. In 2025 it secured IATA corporate-level certification for pharmaceutical ground handling across its air hubs and ramps, and it recently named a VP of global quality, healthcare and life sciences.
Temperature-sensitive shipments are supported by FedEx Surround, a machine-learning-based monitoring and intervention service that flags potential disruptions such as delays or temperature deviations. Nick Gennari, a 30-plus-year FedEx veteran who has led the healthcare vertical since 2024, was named president of the new healthcare and life sciences organization.
Key Takeaway
FedEx's consolidated life sciences unit signals deeper investment in premium, high-margin healthcare logistics — a space where reliability and cold-chain integrity matter more than price, and one to watch as carriers compete for pharma and biotech customers.
Source: